Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ITGR
ITGR logo

ITGR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
87.070
Open
86.970
VWAP
86.71
Vol
58.70K
Mkt Cap
2.98B
Low
86.490
Amount
5.09M
EV/EBITDA(TTM)
11.06
Total Shares
34.07M
EV
4.18B
EV/OCF(TTM)
21.30
P/S(TTM)
1.66
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
Show More

Events Timeline

(ET)
2026-04-06
17:10:00
Integer Chair Pamela Bailey Will Not Seek Re-Election
select
2026-03-12 (ET)
2026-03-12
08:20:00
Integer Holdings Appoints James Flanagan as Independent Director
select
2026-02-19 (ET)
2026-02-19
16:20:00
Walmart Announces $30 Billion Share Buyback Plan
select
2026-02-19
12:10:00
Major U.S. Indices Decline as Walmart Announces $30B Buyback Plan
select
2026-02-19
08:10:00
Integer Reports Q4 Revenue of $472M, Beating Expectations
select
2026-02-19
08:10:00
Sees FY26 Revenue of $1.826B-$1.876B
select

News

Newsfilter
5.0
04-06Newsfilter
Integer Holdings Board Chair Transition Announced
  • Board Chair Transition: Integer Holdings Corporation announced that current independent Chair Pamela G. Bailey will not seek re-election, with the transition set for the Annual Meeting on May 20, 2026, indicating a significant governance shift for the company.
  • New Chair Background: Current director Donald J. Spence will assume the chair position; having served on the board since 2016, he has been pivotal in guiding the company's strategic direction, and is expected to continue advancing long-term value creation strategies.
  • Leadership Confidence: Bailey expressed confidence in Spence's leadership, believing he will work closely with CEO Payman Khales and the executive team to further support the company's growth and strategic success, reflecting a positive outlook for future developments.
  • Strategic Positioning: Spence emphasized Integer's leading position in the medical device contract development and manufacturing sector, committing to continue driving value creation in the cardiovascular, neuromodulation, and cardiac rhythm management markets to ensure long-term shareholder benefits.
Fool
5.0
03-24Fool
Integer Holdings VP Sells 825 Shares Amid Ongoing Liquidity Management
  • Executive Trading Overview: On March 13, 2026, Integer Holdings' VP Tom Thomas sold 825 shares of common stock in an open-market transaction valued at approximately $70,000, leaving him with 4,381 shares worth about $364,000, indicating a routine liquidity management strategy rather than a shift in conviction.
  • Transaction Proportion Analysis: This sale represented 15.85% of Thomas's direct holdings, reflecting a consistent trading pattern over the past year that aligns with liquidity management rather than signaling negative sentiment about the company's future.
  • Company Financial Performance: Integer Holdings reported $1.85 billion in revenue for fiscal year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, driven primarily by strong growth in its cardio and vascular segments, despite a 28% decline in stock price over the past year.
  • Market Outlook Consideration: While the insider sale appears routine, investors are more focused on whether Integer can convert consistent revenue growth into sustained margin expansion and balance sheet improvement, which will likely have a more significant impact on the company's future market performance.
NASDAQ.COM
5.0
03-24NASDAQ.COM
Integer Holdings Insider Sells Shares
  • Insider Stock Sale: On March 13, 2026, Tom Thomas, VP of Integer Holdings, sold 825 shares of common stock for a total transaction value of $70,000, representing 15.85% of his direct holdings, indicating a liquidity management action by the executive.
  • Transaction Context: The sale was executed via direct ownership without involving any indirect entities or derivative securities, suggesting that this move is routine rather than a shift in confidence, despite the company's stock declining about 28% over the past year.
  • Financial Performance Overview: Integer reported approximately $1.85 billion in sales for full-year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, primarily driven by growth in its cardio and vascular segment through new product ramps and acquisitions.
  • Future Outlook Challenges: Despite consistent revenue growth, the company's leverage remains elevated near 3.0 times EBITDA, with debt increasing to $1.185 billion, prompting investors to consider whether Integer can translate revenue growth into sustained margin expansion and balance sheet improvement.
Globenewswire
7.0
03-20Globenewswire
ASP Isotopes Class Action Survives Dismissal Motion
  • Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes' motion to dismiss, allowing the securities fraud class action to proceed, indicating serious consideration of investor allegations that could lead to significant financial liabilities for the company.
  • False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may undermine investor confidence.
  • Shareholder Rights Protection: Shareholders who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting legal avenues available for affected investors to potentially reclaim losses.
  • Potential Market Impact: As the lawsuit progresses and may result in liability for the company, investor confidence in ASP Isotopes could wane, negatively impacting its stock price and reflecting market concerns over corporate governance and transparency.
Globenewswire
7.0
03-18Globenewswire
ASP Isotopes Class Action Survives Dismissal Motion
  • Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
  • False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
  • Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
  • Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
Yahoo Finance
9.5
03-17Yahoo Finance
Artisan Small Cap Fund Q4 2025 Investor Letter Highlights
  • Portfolio Performance: Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, demonstrating its ability to achieve positive results amid market volatility despite trailing for the full year.
  • Exit from Integer Holdings: The fund exited its investment in Integer Holdings Corporation during Q4 due to unmet earnings growth expectations, revenue slowdown, and lack of margin improvement, compounded by a leadership transition that raised concerns about future profit cycles.
  • Hedge Fund Holdings Shift: By the end of Q4 2025, 32 hedge funds held Integer Holdings, up from 24 in the previous quarter, indicating increased market interest, yet the fund believes that other AI stocks present greater upside potential.
  • Market Environment Impact: The market in 2025 experienced frequent sentiment shifts influenced by U.S. politics, trade policy, and geopolitical tensions, yet the fund remains focused on identifying profit cycles at reasonable valuations to navigate future market challenges.
Wall Street analysts forecast ITGR stock price to rise
4 Analyst Rating
Wall Street analysts forecast ITGR stock price to rise
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
75.00
Averages
86.25
High
95.00
Current: 0.000
sliders
Low
75.00
Averages
86.25
High
95.00
Raymond James
Outperform
maintain
$95 -> $101
AI Analysis
2026-02-23
Reason
Raymond James
Price Target
$95 -> $101
AI Analysis
2026-02-23
maintain
Outperform
Reason
Raymond James raised the firm's price target on Integer to $101 from $95 and keeps an Outperform rating on the shares. The main issue is how and when the company will overcome headwinds from three underperforming products, which are expected to depress growth by 300-400 basis points in 2026, the analyst tells investors in a research note. Recovery is likely by late 2026 as these headwinds ease and new products contribute, positioning the business to target growth roughly 200 bps above the market in 2027, the firm says.
Benchmark
Robert Wasserman
Hold
to
Buy
upgrade
$95
2026-02-20
Reason
Benchmark
Robert Wasserman
Price Target
$95
2026-02-20
upgrade
Hold
to
Buy
Reason
Benchmark analyst Robert Wasserman upgraded Integer to Buy from Hold with a $95 price target after the company reported better-than-expected results for Q4 and announced an additional $50M accelerated share repurchase program. The firm cites "the positive rebound in quarterly financial results" displayed in Q4 for its upgrade.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ITGR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Integer Holdings Corp (ITGR.N) is 16.98, compared to its 5-year average forward P/E of 18.92. For a more detailed relative valuation and DCF analysis to assess Integer Holdings Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.92
Current PE
16.98
Overvalued PE
22.09
Undervalued PE
15.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.78
Current EV/EBITDA
11.27
Overvalued EV/EBITDA
14.24
Undervalued EV/EBITDA
11.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.96
Current PS
1.49
Overvalued PS
2.33
Undervalued PS
1.60

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

so what Company is best for me
Intellectia · 79 candidates
Price: $5.00 - $400.00Relative Vol: >= 3List Exchange: XNYS, XNAS, XASEOne Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ITGR logo
ITGR
Integer Holdings Corp
3.00B
VERX logo
VERX
Vertex Inc
2.12B
SCHW logo
SCHW
Charles Schwab Corp
164.81B
SPHR logo
SPHR
Sphere Entertainment Co
3.95B
IRON logo
IRON
Disc Medicine Inc
2.42B
CRI logo
CRI
Carter's Inc
1.55B
what should I buy to make some quick cash
Intellectia · 29 candidates
Market Cap: >= 2.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
RELY logo
RELY
Remitly Global Inc
2.85B
AVAV logo
AVAV
AeroVironment Inc
13.25B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
16.41B
LBRT logo
LBRT
Liberty Energy Inc
4.39B
VIST logo
VIST
Vista Energy SAB de CV
5.78B
GLBE logo
GLBE
Global-E Online Ltd
5.91B

Whales Holding ITGR

K
Kennedy Capital Management LLC
Holding
ITGR
+10.03%
3M Return
H
Heartland Advisors, Inc.
Holding
ITGR
+6.02%
3M Return
J
J. Goldman & Co., L.P.
Holding
ITGR
-1.16%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Integer Holdings Corp (ITGR) stock price today?

The current price of ITGR is 86.57 USD — it has decreased -1.04

What is Integer Holdings Corp (ITGR)'s business?

Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.

What is the price predicton of ITGR Stock?

Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is86.25 USD with a low forecast of 75.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Integer Holdings Corp (ITGR)'s revenue for the last quarter?

Integer Holdings Corp revenue for the last quarter amounts to 472.06M USD, increased 5.02

What is Integer Holdings Corp (ITGR)'s earnings per share (EPS) for the last quarter?

Integer Holdings Corp. EPS for the last quarter amounts to 1.38 USD, increased 53.33

How many employees does Integer Holdings Corp (ITGR). have?

Integer Holdings Corp (ITGR) has 11000 emplpoyees as of April 09 2026.

What is Integer Holdings Corp (ITGR) market cap?

Today ITGR has the market capitalization of 2.98B USD.